OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
AKZO59

Akzo Nobel NV

Commodity ChemicalsVerified

Akzo Nobel's capital structure is characterized by a debt-to-equity ratio of 1.21, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.1 and negative free cash flow of -64 million EUR, suggesting potential short-term liquidity constraints. Despite holding 1.17 billion EUR in cash and equivalents, the company's long-term debt of 5.42 billion EUR offsets this, resulting in a net cash position that is negative after subtracting total debt. Profitability metrics for Akzo Nobel show a return on equity (ROE) of 3.96% and a return on assets (ROA) of 1.22%, both of which are below the industry median for Commodity Chemicals. The company's operating margin is 9.7%, which is also below the median for its industry, indicating that it is underperforming in terms of converting revenue into operating profit. Geographically, Akzo Nobel's revenue is concentrated in Europe, with a significant portion derived from its Paints and Coatings segment. The company's exposure to emerging markets is limited, and its revenue concentration in a few key regions could pose a risk in the event of regional economic downturns or geopolitical instability. Akzo Nobel's growth trajectory is modest, with revenue of 2.78 billion EUR in the latest reporting period. The company's capital expenditures of -115 million EUR suggest a reduction in investment in new projects or facilities, which could impact long-term growth potential. Analysts have provided a mean price target of 61.75 EUR, with a median of 63.00 EUR, indicating a generally positive outlook despite the company's current financial challenges. Risk factors for Akzo Nobel include its high debt load and negative free cash flow, which could limit its ability to invest in growth opportunities or withstand economic downturns. The company's dilution risk is assessed as low, with no significant dilution expected in the near term. However, the company's reliance on debt financing and its exposure to volatile commodity prices could increase financial risk in the future. Recent events for Akzo Nobel include the release of its latest financial results, which show a decline in operating cash flow and free cash flow. The company has also announced plans to reduce capital expenditures in the coming year, which could impact its ability to maintain or grow its market share. Analysts have provided a range of price targets, with a mean of 61.75 EUR and a median of 63.00 EUR, indicating a generally positive outlook despite the company's current financial challenges.

30-day price · AKZO-1.90 (-3.7%)
Low$47.50High$55.12Close$49.00As of17 May, 00:00 UTC
Profile
CompanyAkzo Nobel NV
TickerAKZO.AS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Akzo Nobel NV is a global leader in paints and specialty chemicals, generating revenue primarily through the sale of coatings, performance chemicals, and functional materials.

Classification. Akzo Nobel is classified in the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry with a confidence level of 0.92.

Akzo Nobel's capital structure is characterized by a debt-to-equity ratio of 1.21, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.1 and negative free cash flow of -64 million EUR, suggesting potential short-term liquidity constraints. Despite holding 1.17 billion EUR in cash and equivalents, the company's long-term debt of 5.42 billion EUR offsets this, resulting in a net cash position that is negative after subtracting total debt. Profitability metrics for Akzo Nobel show a return on equity (ROE) of 3.96% and a return on assets (ROA) of 1.22%, both of which are below the industry median for Commodity Chemicals. The company's operating margin is 9.7%, which is also below the median for its industry, indicating that it is underperforming in terms of converting revenue into operating profit. Geographically, Akzo Nobel's revenue is concentrated in Europe, with a significant portion derived from its Paints and Coatings segment. The company's exposure to emerging markets is limited, and its revenue concentration in a few key regions could pose a risk in the event of regional economic downturns or geopolitical instability. Akzo Nobel's growth trajectory is modest, with revenue of 2.78 billion EUR in the latest reporting period. The company's capital expenditures of -115 million EUR suggest a reduction in investment in new projects or facilities, which could impact long-term growth potential. Analysts have provided a mean price target of 61.75 EUR, with a median of 63.00 EUR, indicating a generally positive outlook despite the company's current financial challenges. Risk factors for Akzo Nobel include its high debt load and negative free cash flow, which could limit its ability to invest in growth opportunities or withstand economic downturns. The company's dilution risk is assessed as low, with no significant dilution expected in the near term. However, the company's reliance on debt financing and its exposure to volatile commodity prices could increase financial risk in the future. Recent events for Akzo Nobel include the release of its latest financial results, which show a decline in operating cash flow and free cash flow. The company has also announced plans to reduce capital expenditures in the coming year, which could impact its ability to maintain or grow its market share. Analysts have provided a range of price targets, with a mean of 61.75 EUR and a median of 63.00 EUR, indicating a generally positive outlook despite the company's current financial challenges.
Key takeaways
  • Akzo Nobel's debt-to-equity ratio of 1.21 indicates a moderate reliance on debt financing.
  • The company's ROE of 3.96% and ROA of 1.22% are below the industry median, suggesting underperformance in profitability.
  • Revenue is concentrated in Europe, with limited exposure to emerging markets.
  • Analysts have provided a generally positive outlook, with a mean price target of 61.75 EUR.
  • The company's liquidity position is assessed as medium, with a current ratio of 1.1 and negative free cash flow.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue$2.78B
Gross profit$1.14B
Operating income$270.0M
Net income$177.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$23.0M
CapEx-$115.0M
Free cash flow-$64.0M
Total assets$14.48B
Total liabilities$10.01B
Total equity$4.47B
Cash & equivalents$1.17B
Long-term debt$5.42B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$9.59B$1.12B$829.0M$531.0M
FY-3$10.85B$708.0M$352.0M$85.0M
FY-2$10.67B$983.0M$442.0M$191.0M
FY-1$10.71B$932.0M$542.0M$319.0M
FY0$10.16B$1.14B$635.0M$359.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$13.88B$5.42B
FY-3$14.74B$4.33B
FY-2$14.56B$4.32B
FY-1$14.25B$4.57B
FY0$13.95B$4.66B$829.0M
PeriodOCFCapExFCFSBC
FY-4$604.0M-$288.0M$531.0M
FY-3$254.0M-$292.0M$85.0M
FY-2$1.12B-$286.0M$191.0M
FY-1$668.0M-$306.0M$319.0M
FY0$914.0M-$309.0M$359.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$2.78B$270.0M$177.0M-$64.0M
FQ-6$2.67B$259.0M$163.0M$184.0M
FQ-5$2.62B$142.0M$21.0M-$83.0M
FQ-4$2.61B$192.0M$107.0M$138.0M
FQ-3$2.63B$214.0M$124.0M-$114.0M
FQ-2$2.55B-$29.0M-$194.0M-$189.0M
FQ-1$2.37B$761.0M$598.0M$524.0M
FQ0$2.39B$177.0M$93.0M$133.0M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$14.48B$4.47B$1.17B
FQ-6$15.35B$4.58B$1.96B
FQ-5$14.25B$4.57B$1.30B
FQ-4$14.85B$4.62B$1.60B
FQ-3$14.17B$4.17B$1.55B
FQ-2$13.90B$3.93B$1.32B
FQ-1$13.95B$4.66B$1.62B
FQ0$15.49B$4.88B$2.76B
PeriodOCFCapExFCFSBC
FQ-7-$23.0M-$115.0M-$64.0M
FQ-6$271.0M-$192.0M$184.0M
FQ-5$668.0M-$306.0M-$83.0M
FQ-4-$113.0M-$71.0M$138.0M
FQ-3$121.0M-$143.0M-$114.0M
FQ-2$452.0M-$209.0M-$189.0M
FQ-1$914.0M-$309.0M$524.0M
FQ0-$86.0M-$58.0M$133.0M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$4.47B
Net cash-$4.26B
Current ratio1.1
Debt/Equity1.2
ROA1.2%
ROE4.0%
Cash conversion-13.0%
CapEx/Revenue-4.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricAKZOActivity
Op margin9.7%5.5% medp25 -0.0% · p75 10.8%above median
Net margin6.4%4.1% medp25 0.1% · p75 8.8%above median
Gross margin41.0%20.5% medp25 12.4% · p75 29.7%top quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-4.1%-6.2% medp25 -13.4% · p75 -2.6%above median
Debt / equity121.0%37.1% medp25 10.3% · p75 82.0%top quartile
Observations
IR observations
Mean price target61.75 EUR
Median price target63.00 EUR
High price target73.00 EUR
Low price target47.00 EUR
Mean recommendation2.47 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count5.00
Hold count10.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate3.83 EUR
Last actual EPS3.63 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-01 10:54 UTC#ad49abb3
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 07:33 UTCJob: 2e7b2c46